0001562180-22-005202.txt : 20220617
0001562180-22-005202.hdr.sgml : 20220617
20220617163527
ACCESSION NUMBER: 0001562180-22-005202
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220616
FILED AS OF DATE: 20220617
DATE AS OF CHANGE: 20220617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAUL STEVEN M
CENTRAL INDEX KEY: 0001237564
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36544
FILM NUMBER: 221024413
MAIL ADDRESS:
STREET 1: C/O ELI LITTY & CO
STREET 2: LIIY CORPORATE CENTER DC 1093
CITY: INDIANAPOLIS
STATE: IN
ZIP: 46285
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sage Therapeutics, Inc.
CENTRAL INDEX KEY: 0001597553
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-299-8380
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-06-16
false
0001597553
Sage Therapeutics, Inc.
SAGE
0001237564
PAUL STEVEN M
C/O SAGE THERAPEUTICS, INC.
215 FIRST STREET
CAMBRIDGE
MA
02142
true
false
false
false
Stock Option (Right to Buy)
31.36
2022-06-16
4
A
false
9947.00
0.00
A
2032-06-16
Common Stock
9947.00
9947.00
D
The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Steven M. Paul
2022-06-17
EX-24
2
stevepaulpoa2019.txt
STEVEN PAUL POA 2019
POWER OF ATTORNEY
I, the undersigned, hereby authorize and designate Anne Marie
Cook (SVP, General Counsel), Kimi Iguchi (Chief Financial Officer),
Erin Lanciani (SVP, People and Organizational Strategy), and Jennifer
Fitzpatrick (Vice President, Corporate Counsel) for as long as they
remain employees of Sage Therapeutics, Inc., and Laurie Burlingame of
Goodwin Procter, each acting singly, or their successors in role, to
take the following actions, acting as my agent and attorney-in-fact,
with full power of substitution:
(1) to prepare and sign on my behalf any Form 3, Form 4 or
Form 5 pursuant to Section 16 of the Securities Exchange Act of 1934,
as amended, and to file the same with the Securities and Exchange
Commission, NASDAQ, NYSE, and each stock exchange on which shares of
Common Stock or other securities of Sage Therapeutics, Inc. are
listed, as required by law;
(2) to prepare and sign on my behalf any Form 144
pursuant to the Securities Act of 1933, as amended, and to file the
same with the Securities and Exchange Commission, NASDAQ, NYSE, and
each stock exchange on which shares of Common Stock or other
securities of Sage Therapeutics, Inc. are listed, as required by law;
and
(3) take any other action necessary or proper in
connection with the foregoing.
Unless earlier revoked under the next sentence, this Power of
Attorney shall remain in effect as long as I am an executive officer
or director of Sage Therapeutics, Inc., and shall not be affected by
my subsequent disability or incompetence. I may revoke this Power of
Attorney by written notice delivered, in person or by nationally
recognized courier, to the attention of the SVP, General Counsel of
Sage Therapeutics, Inc.
/s/ Steve Paul
______________________________________________
(Signature of Executive Officer or Director)
Name: Steve Paul
Date: 12/13/2018